4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents

A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrach...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1993-10, Vol.36 (22), p.3361-3370
Hauptverfasser: Johnson, Robert E, Baizman, Eugene R, Becker, Carolyn, Bohnet, Eric A, Bell, Rebecca H, Birsner, Nancy C, Busacca, Carl A, Carabateas, Philip M, Chadwick, Christopher C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3370
container_issue 22
container_start_page 3361
container_title Journal of medicinal chemistry
container_volume 36
creator Johnson, Robert E
Baizman, Eugene R
Becker, Carolyn
Bohnet, Eric A
Bell, Rebecca H
Birsner, Nancy C
Busacca, Carl A
Carabateas, Philip M
Chadwick, Christopher C
description A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.
doi_str_mv 10.1021/jm00074a017
format Article
fullrecord <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_jm00074a017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_TPS_2PFG4ZG1_S</sourcerecordid><originalsourceid>FETCH-LOGICAL-a383t-fcbd9ffb4e0e285b7be252cfc936d62677e336f8e261855aea74fbc4465d0c2b3</originalsourceid><addsrcrecordid>eNpt0MFPwjAUBvDGaBDRk2cTDiYepNq-dt3wZlDAhCgJePHSdF0rxbGRdhjnX-8MhHjw9A7fLy_vfQidU3JDCdDb5YoQEnNFaHyA2jQCgnlC-CFqEwKAQQA7RichLBvGKLAWaiXACAXRRmPei_CDW9SZLzHF64Up6hzTMYYex6kpvsvMqW-zdoUJd93n8tPkXVVUTnm_qKvFyumuejdFFU7RkVV5MGe72UGvw8f5YIwnL6Onwf0EK5awCludZn1rU26IgSRK49RABNrqPhOZABHHhjFhEwOCJlGkjIq5TTXnIsqIhpR10PV2r_ZlCN5YufZupXwtKZG_dcg_dTT6YqvXm3Rlsr3d_d_kl7tcBa1y61WhXdgzlnBgfd4wvGUuVOZrHyv_IUXM4kjOpzMJ0-GIv42onDX-auuVDnJZbnzRVPLvgT-Mh4Gl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</title><source>MEDLINE</source><source>American Chemical Society Publications</source><creator>Johnson, Robert E ; Baizman, Eugene R ; Becker, Carolyn ; Bohnet, Eric A ; Bell, Rebecca H ; Birsner, Nancy C ; Busacca, Carl A ; Carabateas, Philip M ; Chadwick, Christopher C</creator><creatorcontrib>Johnson, Robert E ; Baizman, Eugene R ; Becker, Carolyn ; Bohnet, Eric A ; Bell, Rebecca H ; Birsner, Nancy C ; Busacca, Carl A ; Carabateas, Philip M ; Chadwick, Christopher C</creatorcontrib><description>A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00074a017</identifier><identifier>PMID: 8230126</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Anti-Arrhythmia Agents - chemical synthesis ; Anti-Arrhythmia Agents - pharmacology ; Antiarythmic agents ; Arrhythmias, Cardiac - drug therapy ; Benzodiazepines - chemical synthesis ; Benzodiazepines - pharmacology ; Biological and medical sciences ; Cardiovascular system ; Cats ; Disease Models, Animal ; Dogs ; Guinea Pigs ; Heart Ventricles - drug effects ; Male ; Medical sciences ; Myocardial Contraction - drug effects ; Myocardial Contraction - physiology ; Myocardial Infarction - drug therapy ; Pharmacology. Drug treatments ; Potassium Channels - drug effects ; Potassium Channels - physiology ; Rats ; Rats, Sprague-Dawley ; Refractory Period, Electrophysiological - drug effects ; Sodium Channels - drug effects ; Sodium Channels - physiology ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 1993-10, Vol.36 (22), p.3361-3370</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a383t-fcbd9ffb4e0e285b7be252cfc936d62677e336f8e261855aea74fbc4465d0c2b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm00074a017$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm00074a017$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3842394$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8230126$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johnson, Robert E</creatorcontrib><creatorcontrib>Baizman, Eugene R</creatorcontrib><creatorcontrib>Becker, Carolyn</creatorcontrib><creatorcontrib>Bohnet, Eric A</creatorcontrib><creatorcontrib>Bell, Rebecca H</creatorcontrib><creatorcontrib>Birsner, Nancy C</creatorcontrib><creatorcontrib>Busacca, Carl A</creatorcontrib><creatorcontrib>Carabateas, Philip M</creatorcontrib><creatorcontrib>Chadwick, Christopher C</creatorcontrib><title>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.</description><subject>Animals</subject><subject>Anti-Arrhythmia Agents - chemical synthesis</subject><subject>Anti-Arrhythmia Agents - pharmacology</subject><subject>Antiarythmic agents</subject><subject>Arrhythmias, Cardiac - drug therapy</subject><subject>Benzodiazepines - chemical synthesis</subject><subject>Benzodiazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Cats</subject><subject>Disease Models, Animal</subject><subject>Dogs</subject><subject>Guinea Pigs</subject><subject>Heart Ventricles - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocardial Contraction - drug effects</subject><subject>Myocardial Contraction - physiology</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium Channels - drug effects</subject><subject>Potassium Channels - physiology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Refractory Period, Electrophysiological - drug effects</subject><subject>Sodium Channels - drug effects</subject><subject>Sodium Channels - physiology</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MFPwjAUBvDGaBDRk2cTDiYepNq-dt3wZlDAhCgJePHSdF0rxbGRdhjnX-8MhHjw9A7fLy_vfQidU3JDCdDb5YoQEnNFaHyA2jQCgnlC-CFqEwKAQQA7RichLBvGKLAWaiXACAXRRmPei_CDW9SZLzHF64Up6hzTMYYex6kpvsvMqW-zdoUJd93n8tPkXVVUTnm_qKvFyumuejdFFU7RkVV5MGe72UGvw8f5YIwnL6Onwf0EK5awCludZn1rU26IgSRK49RABNrqPhOZABHHhjFhEwOCJlGkjIq5TTXnIsqIhpR10PV2r_ZlCN5YufZupXwtKZG_dcg_dTT6YqvXm3Rlsr3d_d_kl7tcBa1y61WhXdgzlnBgfd4wvGUuVOZrHyv_IUXM4kjOpzMJ0-GIv42onDX-auuVDnJZbnzRVPLvgT-Mh4Gl</recordid><startdate>19931029</startdate><enddate>19931029</enddate><creator>Johnson, Robert E</creator><creator>Baizman, Eugene R</creator><creator>Becker, Carolyn</creator><creator>Bohnet, Eric A</creator><creator>Bell, Rebecca H</creator><creator>Birsner, Nancy C</creator><creator>Busacca, Carl A</creator><creator>Carabateas, Philip M</creator><creator>Chadwick, Christopher C</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19931029</creationdate><title>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</title><author>Johnson, Robert E ; Baizman, Eugene R ; Becker, Carolyn ; Bohnet, Eric A ; Bell, Rebecca H ; Birsner, Nancy C ; Busacca, Carl A ; Carabateas, Philip M ; Chadwick, Christopher C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a383t-fcbd9ffb4e0e285b7be252cfc936d62677e336f8e261855aea74fbc4465d0c2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Animals</topic><topic>Anti-Arrhythmia Agents - chemical synthesis</topic><topic>Anti-Arrhythmia Agents - pharmacology</topic><topic>Antiarythmic agents</topic><topic>Arrhythmias, Cardiac - drug therapy</topic><topic>Benzodiazepines - chemical synthesis</topic><topic>Benzodiazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Cats</topic><topic>Disease Models, Animal</topic><topic>Dogs</topic><topic>Guinea Pigs</topic><topic>Heart Ventricles - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocardial Contraction - drug effects</topic><topic>Myocardial Contraction - physiology</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium Channels - drug effects</topic><topic>Potassium Channels - physiology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Refractory Period, Electrophysiological - drug effects</topic><topic>Sodium Channels - drug effects</topic><topic>Sodium Channels - physiology</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnson, Robert E</creatorcontrib><creatorcontrib>Baizman, Eugene R</creatorcontrib><creatorcontrib>Becker, Carolyn</creatorcontrib><creatorcontrib>Bohnet, Eric A</creatorcontrib><creatorcontrib>Bell, Rebecca H</creatorcontrib><creatorcontrib>Birsner, Nancy C</creatorcontrib><creatorcontrib>Busacca, Carl A</creatorcontrib><creatorcontrib>Carabateas, Philip M</creatorcontrib><creatorcontrib>Chadwick, Christopher C</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnson, Robert E</au><au>Baizman, Eugene R</au><au>Becker, Carolyn</au><au>Bohnet, Eric A</au><au>Bell, Rebecca H</au><au>Birsner, Nancy C</au><au>Busacca, Carl A</au><au>Carabateas, Philip M</au><au>Chadwick, Christopher C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1993-10-29</date><risdate>1993</risdate><volume>36</volume><issue>22</issue><spage>3361</spage><epage>3370</epage><pages>3361-3370</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 microM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for ventricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>8230126</pmid><doi>10.1021/jm00074a017</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1993-10, Vol.36 (22), p.3361-3370
issn 0022-2623
1520-4804
language eng
recordid cdi_crossref_primary_10_1021_jm00074a017
source MEDLINE; American Chemical Society Publications
subjects Animals
Anti-Arrhythmia Agents - chemical synthesis
Anti-Arrhythmia Agents - pharmacology
Antiarythmic agents
Arrhythmias, Cardiac - drug therapy
Benzodiazepines - chemical synthesis
Benzodiazepines - pharmacology
Biological and medical sciences
Cardiovascular system
Cats
Disease Models, Animal
Dogs
Guinea Pigs
Heart Ventricles - drug effects
Male
Medical sciences
Myocardial Contraction - drug effects
Myocardial Contraction - physiology
Myocardial Infarction - drug therapy
Pharmacology. Drug treatments
Potassium Channels - drug effects
Potassium Channels - physiology
Rats
Rats, Sprague-Dawley
Refractory Period, Electrophysiological - drug effects
Sodium Channels - drug effects
Sodium Channels - physiology
Structure-Activity Relationship
title 4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A52%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines:%20Novel%20antiarrhythmic%20agents&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Johnson,%20Robert%20E&rft.date=1993-10-29&rft.volume=36&rft.issue=22&rft.spage=3361&rft.epage=3370&rft.pages=3361-3370&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm00074a017&rft_dat=%3Cistex_cross%3Eark_67375_TPS_2PFG4ZG1_S%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8230126&rfr_iscdi=true